scholarly journals Application of neurotoxin- and pesticide-induced animal models of Parkinson’s disease in the evaluation of new drug delivery systems

2021 ◽  
Vol 72 (1) ◽  
pp. 35-58
Author(s):  
Yaquelyn Casanova ◽  
Sofia Negro ◽  
Emilia Barcia
Keyword(s):  
Parkinson’S Disease ◽  
Drug Delivery ◽  
Parkinson's Disease ◽  
Animal Models ◽  
Drug Delivery Systems ◽  
Unmet Need ◽  
Delivery Systems ◽  
New Drug ◽  
6 Hydroxydopamine ◽  
New Treatments

Abstract Parkinson’s disease (PD) is the second most prevalent neuro-degenerative disease after Alzheimer´s disease. It is characterized by motor symptoms such as akinesia, bradykinesia, tremor, rigidity, and postural abnormalities, due to the loss of nigral dopaminergic neurons and a decrease in the dopa-mine contents of the caudate-putamen structures. To this date, there is no cure for the disease and available treatments are aimed at controlling the symptoms. Therefore, there is an unmet need for new treatments for PD. In the past decades, animal models of PD have been proven to be valuable tools in elucidating the nature of the pathogenic processes involved in the disease, and in designing new pharmacological approaches. Here, we review the use of neurotoxin-induced and pesticide-induced animal models of PD, specifically those induced by rotenone, paraquat, maneb, MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and 6-OHDA (6-hydroxydopamine), and their application in the development of new drug delivery systems for PD.

scholarly journals Brain aging and Parkinson’s disease: New therapeutic approaches using drug delivery systems

Maturitas ◽  
2016 ◽  
Vol 84 ◽  
pp. 25-31 ◽  
Author(s):  
C. Rodríguez-Nogales ◽  
E. Garbayo ◽  
M.M. Carmona-Abellán ◽  
M.R. Luquin ◽  
M.J. Blanco-Prieto
Keyword(s):  
Parkinson’S Disease ◽  
Drug Delivery ◽  
Parkinson's Disease ◽  
Drug Delivery Systems ◽  
Brain Aging ◽  
Delivery Systems ◽  
Therapeutic Approaches ◽  
New Therapeutic Approaches

Orally Administered Nanotherapeutics For Parkinson’s Disease: An Old Delivery System Yet More Acceptable

2020 ◽  
Vol 26 (19) ◽  
pp. 2280-2290 ◽  
Author(s):  
Nidhi Aggarwal ◽  
Zufika Qamar ◽  
Saleha Rehman ◽  
Sanjula Baboota ◽  
Javed Ali
Keyword(s):  
Parkinson’S Disease ◽  
Drug Delivery ◽  
Parkinson's Disease ◽  
Drug Delivery Systems ◽  
Neurodegenerative Disorder ◽  
Intestinal Barrier ◽  
Oral Route ◽  
Delivery Systems ◽  
The Body ◽  
Area Of Interest

As per the present global scenario, Parkinson’s disease (PD) is considered to be the second most common neurodegenerative disorder which is a keen area of interest among researchers. The conventional therapies generally employed against PD are associated with serious drawbacks including limited transport across selectively permeable BBB, hepatic metabolism, intestinal barrier, etc. This urges the need to develop novel therapeutic alternatives. The oral route being the most preferred route of administration needs to be explored for new and more intelligent drug delivery systems. Nanotechnology has been proposed to play a promising role in reversing the progression of the disease via the oral route. Nanocarriers, namely nanoparticles, lipid nanoparticles, nanoemulsions, nanocrystals, nanomicellar formulations, self-nanoemulsifying drug delivery systems and alginate nanocomposites have been investigated upon to modulate the fate of drugs inside the human body when administered orally. The development of various nanotherapeutics for the treatment of PD has been reviewed, depicting an enhanced bioavailability to provide a desired therapeutic outcome. The new advances in the therapy have been explored and highlighted through the body of this review. However, a therapeutically effective concentration at the target site remains a challenge, therefore extensive exploration in the field of nanotherapeutics may facilitate superior drug delivery to CNS via oral route thereby improving the state of disease progression.

Applications of Exosomes in Targeted Drug Delivery for the Treatment of Parkinson’s Disease: A Review of Recent Advances and Clinical Challenges

2020 ◽  
Vol 20 (30) ◽  
pp. 2777-2788
Author(s):  
Bhumika Kumar ◽  
Mukesh Pandey ◽  
Faizana Fayaz ◽  
Tareq Abu Izneid ◽  
Faheem Hyder Pottoo ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Drug Delivery ◽  
Parkinson's Disease ◽  
Substantia Nigra ◽  
Mammalian Cells ◽  
Drug Delivery Systems ◽  
Drug Carrier ◽  
Delivery Systems ◽  
Brain Targeting ◽  
The Brain

Parkinson’s disease (PD) is one of the most prevalent and severe neurodegenerative disease affecting more than 6.1 million people globally. It is characterized by age-related progressive deterioration of neurological functions caused by neuronal damage or neuronal death. During PD, the dopamineproducing cells in the substantia nigra region of the brain degenerate, which leads to symptoms like resting tremors and rigidity. Treatment of PD is very challenging due to the blood-brain barrier, which restricts the drug from reaching the brain. Conventional drug delivery systems possess a limited capacity to cross the blood barrier, leading to low bioavailability and high toxicity (due to off-site drug release). Therefore, it becomes necessary to accelerate the development of novel drug delivery systems, including nanoparticles, microemulsions, matrix systems, solid dispersions, liposomes, and solid lipid nanoparticles for the treatment of PD. Exosomes are biological lipid bilayer membrane vesicles produced by nearly all mammalian cells. The characteristics of vesicles are unique to their cell of origin and are primarily involved in intracellular communication. Exosomes, due to their nanoscale size, could easily permeate across the central nervous system, which makes them ideal for targeting the neurons in the substantia nigra. Exosomes could be efficient drug carrier systems for brain targeting, which can increase the efficacy of the drug and minimize the side effects. The review aims at providing a broad updated view of exosomes and their application in the treatment of PD.

scholarly journals Potential of microemulsified entacapone drug delivery systems in the management of acute Parkinson's disease

2016 ◽  
Vol 5 (4) ◽  
pp. 315-325 ◽  
Author(s):  
Harini Chowdary Vadlamudi ◽  
Prasanna Raju Yalavarthi ◽  
Basaveswara Rao Mandava Venkata ◽  
Jyotsna Thanniru ◽  
Vandana K.R. ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Drug Delivery ◽  
Parkinson's Disease ◽  
Drug Delivery Systems ◽  
Delivery Systems

New non-oral drug delivery systems for Parkinson's disease treatment

2011 ◽  
Vol 8 (3) ◽  
pp. 359-374 ◽  
Author(s):  
Shadab Md ◽  
Shadabul Haque ◽  
Jasjeet Kaur Sahni ◽  
Sanjula Baboota ◽  
Javed Ali
Keyword(s):  
Parkinson’S Disease ◽  
Drug Delivery ◽  
Parkinson's Disease ◽  
Drug Delivery Systems ◽  
Oral Drug Delivery ◽  
Delivery Systems ◽  
Oral Drug ◽  
Disease Treatment ◽  
Oral Drug Delivery Systems

scholarly journals Therapeutic Effects of Hydrogen in Animal Models of Parkinson's Disease

2011 ◽  
Vol 2011 ◽  
pp. 1-9 ◽  
Author(s):  
Kyota Fujita ◽  
Yusaku Nakabeppu ◽  
Mami Noda
Keyword(s):  
Oxidative Stress ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Animal Models ◽  
Animal Studies ◽  
Clinical Symptoms ◽  
Therapeutic Effects ◽  
Therapeutic Approaches ◽  
Cellular Apoptosis ◽  
6 Hydroxydopamine

Since the first description of Parkinson's disease (PD) nearly two centuries ago, a number of studies have revealed the clinical symptoms, pathology, and therapeutic approaches to overcome this intractable neurodegenerative disease. 1-methy-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 6-hydroxydopamine (6-OHDA) are neurotoxins which produce Parkinsonian pathology. From the animal studies using these neurotoxins, it has become well established that oxidative stress is a primary cause of, and essential for, cellular apoptosis in dopaminergic neurons. Here, we describe the mechanism whereby oxidative stress evokes irreversible cell death, and propose a novel therapeutic strategy for PD using molecular hydrogen. Hydrogen has an ability to reduce oxidative damage and ameliorate the loss of nigrostriatal dopaminergic neuronal pathway in two experimental animal models. Thus, it is strongly suggested that hydrogen might provide a great advantage to prevent or minimize the onset and progression of PD.

Sign in / Sign up

Export Citation Format

Share Document